S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

iCAD Stock Forecast, Price & News

-0.10 (-1.62%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
177,251 shs
Average Volume
341,370 shs
Market Capitalization
$152.91 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

iCAD logo

About iCAD

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.


iCAD: Downside Seems Limited - Seeking Alpha
January 16, 2022 |  seekingalpha.com
iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues
January 4, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$29.70 million
Book Value
$1.33 per share


Net Income
$-17.61 million
Pretax Margin




Free Float
Market Cap
$152.91 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.40 out of 5 stars

Computer And Technology Sector

215th out of 888 stocks

Surgical & Medical Instruments Industry

20th out of 130 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

iCAD (NASDAQ:ICAD) Frequently Asked Questions

Is iCAD a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" iCAD stock.
View analyst ratings for iCAD
or view top-rated stocks.

How has iCAD's stock price been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICAD stock has decreased by 45.2% and is now trading at $6.09.
View which stocks have been most impacted by COVID-19

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for iCAD

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings results on Tuesday, November, 9th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. The technology company earned $9.36 million during the quarter, compared to the consensus estimate of $9.41 million. iCAD had a negative net margin of 23.98% and a negative trailing twelve-month return on equity of 17.38%. During the same quarter in the previous year, the business posted ($0.08) EPS.
View iCAD's earnings history

What price target have analysts set for ICAD?

8 Wall Street analysts have issued 1 year target prices for iCAD's shares. Their forecasts range from $13.00 to $24.00. On average, they expect iCAD's stock price to reach $20.38 in the next twelve months. This suggests a possible upside of 234.6% from the stock's current price.
View analysts' price targets for iCAD
or view top-rated stocks among Wall Street analysts.

Who are iCAD's key executives?

iCAD's management team includes the following people:

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD CEO Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among iCAD's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.09%). Company insiders that own iCAD stock include Andy Sassine, Charles Ross Carter, Jonathan Go, Michael S Klein, R Scott Areglado, Stacey M Stevens and Susan Alyson Wood.
View institutional ownership trends for iCAD

Which major investors are selling iCAD stock?

ICAD stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have sold iCAD company stock in the last year include Andy Sassine, Jonathan Go, and Stacey M Stevens.
View insider buying and selling activity for iCAD
or view top insider-selling stocks.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $6.09.

How much money does iCAD make?

iCAD has a market capitalization of $152.91 million and generates $29.70 million in revenue each year. The technology company earns $-17.61 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 114 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

Where are iCAD's headquarters?

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at (603) 882-5200, via email at [email protected], or via fax at 603-880-3843.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.